Physician profile
Eric Ball
NPI 1316032972
$17,647.47
in general payments reported to CMS, 2019-2025
24 companies · $642 in 2025
The $642 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,041 · 2020: $4,287 · 2021: $918 · 2022: $1,928 · 2023: $4,420 · 2024: $1,412 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,892 · Food and Beverage: $1,583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,891.50 |
| Food and Beverage | $1,582.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $11,356.30 | 2019-2025 | Vaxneuvance, Vaxelis, M-M-R II |
| Seqirus USA INC | $4,057.51 | 2023-2024 | Flucelvax Quadrivalent |
| Ironshore Pharmaceuticals INC. | $336.41 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $333.51 | 2021-2025 | Quillivant, Quillichew Er, Dyanavel Xr |
| Sanofi Pasteur INC. | $268.10 | 2019-2025 | |
| Glaxosmithkline, LLC. | $225.46 | 2019-2025 | Bexsero, Penmenvy |
| Adlon Therapeutics L.P. | $172.61 | 2020-2021 | |
| Kaleo, INC. | $148.75 | 2019-2023 | Auvi-Q |
| Pfizer INC. | $112.51 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $109.44 | 2024-2025 | |
| Cognoa, INC. | $82.98 | 2022 | |
| Mirum Pharmaceuticals, INC. | $80.02 | 2025 | Cholbam |
| Alk-Abello, INC | $54.37 | 2025 | Neffy |
| Vertical Pharmaceuticals, LLC | $48.12 | 2024 | Relexxii |
| Collegium Pharmaceutical, INC. | $41.19 | 2025 | Jornay Pm |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $33.54 | 2023-2025 | Doc Band |
| Neos Therapeutics, Lp | $33.41 | 2025 | Cotempla Xr-Odt |
| Supernus Pharmaceuticals, INC. | $33.26 | 2024 | Qelbree |
| Ultragenyx Pharmaceutical INC. | $25.21 | 2022 | |
| Corium, LLC | $23.59 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.33 | 2023 | Elaprase |
| Ars Pharmaceuticals Operations, INC. | $19.34 | 2025 | Neffy |
| Abbvie INC. | $15.25 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.26 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Ball listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.